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The clinical and phenotypic assessment of seronegative villous atrophy; a prospective UK centre 
experience evaluating 200 adult cases over a 15 year period (2000-2015)  
ABSTRACT 
Background: Seronegative villous atrophy (SNVA) is commonly attributed to coeliac disease. 
However, there are other causes of SNVA. More recently angiotensin-2-receptor-blockers have been 
reported as an association but data on SNVA has been limited to centres evaluating complex case 
referrals and not SNVA in general.  
Objectives: To provide clinical outcomes and associations in a large prospective study overseeing all 
newcomers with SNVA. 
Design: Over a 15-year period (2000-2015) we evaluated 200 adult patients with SNVA at a UK 
centre. A diagnosis of either seronegative coeliac disease (SNCD) or SN-non-CD was reached. 
Baseline comparisons were made between the groups, with 343 seropositive CD subjects serving as 
controls. 
 
Results: Of the 200 SNVA cases, SNCD represented 31% (n=62) and SN-non-CD 69% (n=138). The 
HLA-DQ2 and/or DQ8 genotype was present in 61%, with a 51% positive predictive value for SNCD. 
The breakdown of identifiable causes in the SN-non-CD group comprised infections (27%, n=54), 
inflammatory/immune-mediated disorders (17.5%, n=35) and drugs (6.5%, n=13; two cases related 
to angiotensin-2-receptor-blockers). However, no cause was found in 18% (n=36) and of these 72% 
(n=26/36) spontaneously normalised duodenal histology whilst consuming a gluten-enriched diet.  
 
Following multivariable logistic regression analysis an independent factor associated with SN-non-CD 
was non-white ethnicity (odds ratio 10.8, 95% confidence interval 2.2-52.8); in fact, 66% of non-
whites had gastrointestinal infections. On immunohistochemistry all groups stained positive for CD8-
T-cytotoxic intraepithelial lymphocytes. However, additional CD4-T-helper intraepithelial 
lymphocytes were occasionally seen in SN-non-CD mimicking the changes associated with refractory 
CD. 
 
Conclusions: Most patients with SNVA do not have coeliac disease, in particular those who are not 
white. Furthermore, a subgroup with no obvious aetiology will show spontaneous histological 
resolution whilst consuming gluten. These findings suggest caution in empirically prescribing a 
gluten-free diet without investigation. 
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Significance of this study 
What is already known on this subject? 
Seronegative villous atrophy (SNVA) is a diagnostic and therapeutic dilemma. 
The causes of SNVA are vast but can be broadly grouped into seronegative CD (SNCD) and SN-non-
CD. 
To date no study has systematically evaluated all newcomers with SNVA. 
What are the new findings? 
SNCD accounts for 31% of SNVA cases, with the remaining 69% due to SN-non-CD. 
A positive HLA-DQ2 and/or DQ8 status is seen in 61% of SNVA cases; its positive predictive value for 
SNCD is roughly 51%. 
An independent risk factor associated with SN-non-CD is non-white ethnicity, suggestive of infective 
aetiology. 
Overall, almost one-in-five SNVA patients will have no identifiable cause; reassuringly, the majority 
of these will spontaneously normalise duodenal histology despite undertaking a gluten challenge. 
How might it impact on clinical practice in the foreseeable future? 
Individuals with SNVA should not be prescribed a gluten-free diet prior to further investigations. This 
is because of the wide differential diagnoses and that a subgroup with no obvious aetiology 
spontaneously normalise their duodenal histology whilst maintaining gluten intake. 
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Introduction 
Coeliac disease (CD) affects 0.7-1% of the population and can be defined as a state of heightened 
immune response to ingested gluten in genetically susceptible individuals.1,2 All patients with CD 
carry the HLA-DQ2 and/or DQ8 genotypes, although these alleles are also present in approximately 
40% of the general population.3 A cast-iron diagnosis of CD can be made on the basis of 
demonstrating duodenal villous atrophy in the presence of serum IgA endomysial and/or tissue 
transglutaminase antibodies.4-6 This mode of presentation may be termed seropositive CD (SPCD) 
and following a systematic review accounts for approximately 93% of cases with villous atrophy,7 
although some international groups have reported a lower prevalence (Table 1).8-15 
With this in regard, diagnostic and therapeutic dilemmas occur when villous atrophy is found in the 
context of negative coeliac serology.8-15 This clinical entity is termed seronegative villous atrophy 
(SNVA), of which the causes can be broadly grouped into CD or non-CD related.16,17 The reasons for 
seronegative CD (SNCD) include patients who have reduced gluten intake prior to investigations,18 
lesser degrees of villous atrophy,13 selective IgA deficiency,19 immunosuppressive therapy, or those 
with long-standing advanced CD within the spectrum of ulcerative jejunitis/enteropathy associated 
T-cell lymphoma.15 The causes of seronegative non-CD (SN-non-CD) are vast ranging from infective, 
inflammatory, immune-mediated and drug-related.16,17 Such examples include autoimmune 
enteropathy,20 bacterial overgrowth,16 common variable immunodeficiency,21 crohn’s disease,22 
gastroenteritis,23 giardiasis,24,25 graft vs. host disease,26 HIV enteropathy,27, mycobacterium 
tuberculosis,25,28 peptic duodentitis +/- helicobacter pylori,17,29-32 radiation enteritis,33 tropical 
sprue,25,34 and Whipple’s disease.35 Medications include non-steroidal anti-inflammatory drugs,36-38 
azathioprine,39 methotrexate,40 mycophenolate mofetil,41 and most recently  angiotensin-2-receptor-
blockers (A2RB), in particular olmesartan.16,42-45 Finally, in some instances no unifying cause can be 
found and such patients are classified as idiopathic/unclassified sprue, the natural history of which is 
unknown.16,17 
Studies attempting to evaluate diagnostic outcomes in SNVA have thus far been limited to a US 
centre overseeing complex case referrals from a wide catchment area.16 In such circumstances a 
high prevalence of SNCD and olmesartan-related enteropathy has been reported, the latter 
accounting for a striking 22% of SNVA cases.16 However, we hypothesise that this may not be 
reflective of SNVA as seen in routine gastrointestinal practice. Furthermore, the clinical and 
histological phenotype of SNCD and SN-non-CD has not been established, nor how these entities 
contrast to the more conventionally seen SPCD. Such an evaluation may prove useful in 
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understanding the spectrum of villous atrophy whilst also aiding clinicians towards the correct 
diagnosis when posed with the challenges of SNVA.  
In light of this, the aim of our study was to provide a large comprehensive overview of all SNVA 
patients seen at a UK centre over a 15 year period. Furthermore, we sought to identify differences 
between SNCD and SN-non-CD, using SPCD as controls. 
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Material and Methods 
Setting 
This study was carried out between the time-periods of 2000 to 2015 at the Royal Hallamshire 
Hospital, Sheffield, South Yorkshire, UK. The hospital is located in Northern England and provides a 
secondary/tertiary-care service to a population of 500 000 people. The unit undertakes 
approximately 6000 oesophagogastroduodenoscopies per year.  
Participants 
Over the 15 year period we prospectively recruited 200 consecutive adult patients presenting with 
SNVA. The identification of SNVA was based upon duodenal biopsies showing villous atrophy yet 
with negative serum IgA endomysial and tissue transglutaminase antibodies from the outset.  
As for our control group we recruited 343 SPCD patients diagnosed within the same department 
between the years 2005 to 2011. 
Histology 
Throughout the study period the gastroenterology department had a policy of taking 4 duodenal 
biopsy specimens from the second part of the duodenum in those with suspected malabsorption. All 
duodenal biopsy specimens were fixed in buffered formalin and embedded in paraffin wax. Standard 
3μm thick sections at 3 levels were stained with haematoxylin and eosin. The duodenal biopsies 
were routinely reported by one of a team of seven gastrointestinal histopathologists. Agreement 
was then performed by one of two expert GI histopathologists reviewing SNVA biopsy samples (co-
authors SSC and PV). Intraepithelial lymphocytosis was defined as >25 per 100 enterocytes. Villous 
atrophy was identified according to the Marsh-Oberhuber criteria, using the most severe lesion 
present: Marsh 3a (partial villous atrophy, PVA); Marsh 3b (subtotal villous atrophy, SVA); or Marsh 
3c (total villous atrophy, TVA).46,47  
The groups were also assessed for differences in immunohistochemistry based on CD3 pan-
lymphocyte marker and specific CD8-T-cytotoxic and CD4-T-helper intraepithelial lymphocyte 
expression. 
Coeliac serology 
The initial panel of coeliac serology testing was IgA based, with endomysial antibodies detected by 
immunofluoresence on primate oesophagus sections from The Binding Site (Birmingham, UK). IgA 
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tissue transglutaminase antibodies were assayed by using enzyme-linked immunosorbent assay kits 
(Aesku Diagnostics, Wendelsheim, Germany), with titres less than or equal to 15 U/ml taken as 
negative. Of note, our immunology department does not automatically test for immunoglobulin or 
total IgA levels when processing coeliac serology. Rather, these have to be specifically requested as 
does IgG coeliac serology. 
Baseline characteristics 
We collected baseline characteristic data on the SNVA and SPCD cohort. Taking into consideration 
the potential aetiologies and clinical manifestations this included age, gender, ethnicity, city 
residence, clinical symptoms, past medical history, current medication, grading of villous atrophy, 
HLA-DQ2/8 status, as well as laboratory parameters in the form of haemoglobin, ferritin, folate, 
vitamin B12, albumin, calcium, erythrocyte sedimentation rate and/or C-reactive protein.  
All the data (other than age) was inputted as categorical. This included converting numerical 
laboratory values into either within the normal or abnormal range, thereby overcoming the 
difficulties that arise over a 15 year period with departmental changes in testing kits and reference 
values. 
Diagnostic work-up for SNVA 
All patients with SNVA were investigated in line with a systematic protocol, similar to that proposed 
by other expert groups, aiming to diagnose either SNCD or SN-non-CD (Figure 1).16,17 It is important 
to bear in mind that, despite several international guidelines on CD, there is no consensus on how to 
approach subjects with SNVA.4-6 Some physicians may suggest a trial of a gluten-free diet (GFD) 
followed by clinical and histological reassessment.4-6 However, this can be fraught with uncertainty 
given that up to 32% of patients with SN-non-CD report favourable clinical response to a GFD.17 
Furthermore, mucosal recovery in adult CD is slow with histological abnormalities often persisting 
beyond 2-5 years and in some cases never normalising.48-50 Therefore, adopting such an approach in 
SNVA could potentially lead to unnecessary delays given the wide differential diagnoses. Hence, 
patients with SNVA in our study were asked to continue a gluten-containing diet until investigations 
were complete and a firm diagnosis reached. This approach is also useful in that it allows 
progression of villous atrophy and detectable serum antibodies in some cases of SNCD.51 
Mortality 
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At the end of December 2015 mortality rates were calculated. Overall survival was calculated in 
years and defined as the time from diagnosis to death. Surviving patients were censored at the time 
of last follow-up.  
Statistics 
Statistical analysis was carried out using SPSS version 21.0 software (SPSS Inc. Chicago, USA), with 
significance set at a p-value of <0.05. A complete-case analysis approach was adopted to address the 
limited data which was missing completely at random. Categorical variables were summarized by 
descriptive statistics, including total numbers and percentages, with comparisons between groups 
performed using the chi-squared or Fisher’s exact test. Normally-distributed continuous variables 
were summarized by mean and standard deviation with comparisons between groups performed 
using the unpaired student’s t-test. We performed dichotomous logistic regression between the 
SNCD and SN-non-CD groups using a forward stepwise method with p-value of <0.1 for entry into the 
analysis with all variables available for inclusion into the model. Finally, overall survival was analysed 
using Kaplan–Meier curves and significance compared using the Log-rank test. 
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Results 
Characteristics of SNVA 
The baseline characteristics of the 200 SNVA patients are provided in Table 2. The patient cohort 
comprised 83% (n=166) who were residents of Sheffield and thus classed as secondary-care 
referrals. There were 17% (n=34) who were referred from another city for a tertiary-care opinion. 
The mean-age was 51.2 years, with 63.5% (n=127) female, and 82.5% (n=165) of white ethnicity.  
The most frequently reported clinical symptoms were diarrhoea (60%, n=120), abdominal pain (49%, 
n=98), weight loss (35.5%, n=71), and bloating (31%, n=62). Autoimmunity was present in 18.5% 
(n=37) of cases, with 3.5% (n=7) also having a family history of CD. A recent history suggestive of 
gastroenteritis was elicited in 11.5% (n=23) of cases. The use of A2RB was seen in 4% (n=8), of which 
7 were on candesartan and 1 was on irbesartan; no patients were taking olmesartan.  
Blood tests revealed anaemia in 30.8%, with associated haematinic deficiencies ranging from 16.1% 
to 39.5%. A raised erythrocyte sedimentation rate and/or C-reactive protein was present in 26.6% of 
patients. The presence of positive HLA DQ2 and/or DQ8 was seen in 61.1% (n=118/193).  
Finally, histological grading of duodenal biopsies showed intraepithelial lymphocytosis in 88.5% 
(n=177), with the majority of patients found to have partial villous atrophy at 79.5% (n=159). In 
contrast, subtotal villous atrophy was seen in 12.5% (n=25) and total villous atrophy in 8% (n=16). 
Aetiology of SNVA 
Following systematic evaluation of 200 SNVA cases, we diagnosed SNCD in 31% (n=62) of cases with 
the remaining 69% (n=138) due to SN-non-CD. The breakdown of all causes is shown in Figure 2. 
In the 62 cases identified as having SNCD, 14 were diagnosed with relative ease based on i) selective 
IgA deficiency but with raised IgG coeliac serology (n=9, three also had associated first degree family 
history of CD), ii) first degree family history of CD alone with subsequent response to a GFD (n=4), 
and iii) dermatitis herpetiformis (n=1). The other 48 patients were diagnosed with SNCD on the basis 
of having positive HLA-DQ2 and/or DQ8 status, no alternate cause found, persisting villous atrophy 
following a gluten re-challenge, with subsequent clinical +/- histological response to a GFD.  
A wide range of aetiologies were established in the 138 SN-non-CD cases, commonly infective, 
medication-induced, and inflammatory in nature. In total, there were 54 cases attributed to an 
infection. This included H.pylori induced duodenitis alone (n=21) or in conjunction with 
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Mycobacterium tuberculosis (n=2), Mycobacterium avium intracellulare (n=1) and HIV (n=1). Other 
causes included viral gastroenteritis based upon clinical history (n=7), giardiasis (n=6), small bowel 
bacterial overgrowth (n=4), HIV enteropathy (n=2), Ascariasis (n=2), Mycobacterium tuberculosis 
(n=2), tropical sprue (n=2), Campylobacter (n=1), Candidiasis (n=1), Whipple’s disease (n=1) and 
Mycobacterium avium intracellulare (n=1). There were 13 cases which occurred as a result of 
medication; 9 due to NSAID-related duodenitis, and the others were a case each related to 
methotrexate, mycophenolate mofetil, irbesartan and a possible association with candesartan. 
There were 23 cases of non-specific peptic duodenitis, 6 cases of Crohn’s disease, and 4 cases due to 
systemic immune-mediated disorders which included a case each of sarcoidosis, graft vs. host 
disease, autoimmune enteropathy and common variable immunodeficiency. There was a case each 
of radiation enteritis and eosinophillic enteritis. Following appropriate treatment these showed 
clinical and histological improvement.  
Finally, in 36 cases of SN-non-CD, despite extensive investigations, we were unable to elicit any 
cause and these patients were labelled as idiopathic/unclassified sprue. Interestingly, 72% (n=26/36, 
eleven of whom were HLA-DQ2/8 positive) had spontaneously normalised their duodenal biopsies 
when re-challenged with gluten, suggesting transient villous atrophy. This was seen on average nine 
months after the index biopsy had shown villous atrophy. Of the remaining 10 cases, all HLA-DQ2/8 
negative, four required immunosuppressive therapy for persisting unexplained villous atrophy with 
the other 6 either lost to follow-up or refusing further endoscopic investigations given their clinical 
stability. 
Risk factors for diagnostic outcomes 
Univariate analysis comparing the SNVA subgroups and SPCD controls are shown in table 2. In 
summary, the SNVA cohort were older at the time of presentation and more likely to present with 
symptoms of diarrhoea, abdominal pain, nausea and weight loss.  
In contrast, subjects with SPCD or SNCD were more likely than SN-non-CD to have autoimmunity, 
family history, and HLA-DQ positivity; however, the positive predictive value of HLA-DQ2/8 for SNCD 
in the context of SNVA was only 51% (n=60/118). There was also a significant trend towards lesser 
degrees of villous atrophy from SPCD towards SNCD and then SN-non-CD.  
Factors significantly associated with SN-non-CD included non-white ethnicity, dyspepsia, negative 
HLA-DQ status, lack of intraepithelial lymphocytosis/crypt hyperplasia, and hypoalbuminemia. 
Multivariable logistic regression analysis of the SNVA cohort showed that an independent factor 
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associated with a diagnosis of SN-non-CD was non-white ethnicity (odds ratio 10.8, 95% confidence 
interval 2.2-52.8, p=0.003). Indeed, 23 of the 35 (66%) non-white subjects presenting with SNVA had 
a gastrointestinal infection, commonly Helicobacter pylori induced duodenitis; Table 3. Only 2 of 35 
(5.7%) non-whites with SNVA had SNCD compared to 60 of 165 (36%) whites. 
Immunophenotyping of intraepithelial lymphocytes 
Immunohistochemistry was performed in 19 SNVA cases of which 14 were SN-non-CD and 5 SNCD. 
Both groups showed CD8 positive T-cytotoxic intraepithelial lymphocytes, similar to that seen in 
SPCD controls. However, 4 cases of SN-non-CD also contained CD4 positive T-helper cells amongst 
the intra-epithelial lymphocytes; these cells are associated with refractory CD within the context of 
CD but in other contexts, such as gastrointestinal infection, they are a normal component of the 
immune response (Figure 3 and Supplementary Figure 1). 
Survival Analysis 
There have been 19 deaths within the 200 SNVA cohort, of which 7/60 (11.2%) were in the SNCD 
group and 12/138 (8.7%) in the SN-non-CD group. In comparison there have been 11/343 (3.2%) 
deaths in the SPCD controls. On Kaplan-Meier there were no statistical differences in estimated 
survival between the SNVA groups although this was less favourable compared to SPCD (Figure 4: log 
rank p=0.002). 
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Discussion 
Main findings 
We believe that our findings represent a major conceptual change in the understanding and 
management of SNVA. Having used a systematic clinical algorithm we have shown that SNCD 
accounts for 31% of SNVA cases, with the remaining 69% due to SN-non-CD related causes. 
Furthermore, HLA-DQ2 and/or DQ8 genotype was present in 61% of SNVA cases, with a positive 
predictive value of only 51% for a diagnosis of SNCD. This is not surprising given that these alleles are 
common as seen in approximately 40% of the general population.3  
Importantly, we have identified that non-white ethnicity is a risk factor to alert clinicians to the 
possibility of SN-non-CD, in particular with regards to an infective aetiology. These findings are the 
first to be reported outside of the Tropics and in a Western society.25 The clinical relevance of this 
also expands to the US where results from a national pathology database have identified that among 
patients undergoing duodenal biopsies it is those from the Punjab region of India that constitute the 
ethnic group with the highest prevalence of villous atrophy.52 It remains to be determined whether 
such patients had SNVA given that the US National Health and Nutrition Examination survey has 
found positive coeliac serology to be rare amongst non-whites.1  
In addition, in almost one-in-five cases of SNVA no identifiable cause was found although, 
reassuringly, the majority spontaneously normalised duodenal histology whilst being investigated on 
a gluten-enriched diet; had these patients been commenced on a GFD at the outset instead then 
they would have erroneously been diagnosed with SNCD and wrongfully subjected to a lifelong, 
restrictive diet. This, along with previous studies showing that an empirical trial of a GFD to be a 
poor predictor of CD,17 further supports the notion that clinicians must not start a GFD in SNVA until 
investigations are complete and a firm diagnosis of SNCD has been established.  
Finally, differences in survival outcomes between SNVA and SPCD controls were noted. A recent 
English study involving more than 10 000 CD patients found no major excess risk of cancer, digestive 
disease or respiratory disease related or cardiovascular mortality compared with the general 
population.53 However, it is recognised that those with SNCD tend to be older and run a more 
advanced disease course than SPCD.15 With regards to SN-non-CD this entity has a number of 
heterogeneous disease associations (i.e. HIV, tuberculosis, common variable immunodeficiency) 
which are associated with poorer outcomes. 
Strengths and limitations 
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The main strength of this study is that it is the largest and most comprehensive to date, having 
prospectively evaluated 200 consecutive adult patients with SNVA at a UK secondary/tertiary-care 
centre over a 15-year period. The cohort studied included both inner and outer city referrals. 
Moreover, systematic and rigorous investigations were performed using testing modalities available 
amongst most gastroenterology departments. We therefore feel that our findings can be used as a 
benchmark and generalized to other physicians seeing similar patients.  
However, our study does have several limitations. Firstly, we do not perform serum deamidated 
gliadin peptide antibodies or intestinal coeliac antibody deposits, both of which are relatively novel 
markers and can aid towards the diagnosis of CD.54-56 Secondly, it may also be perceived that by 
identifying and including IgA deficient patients who were subsequently found to be IgG coeliac 
serology positive (n=9) is a weakness in that this should be common knowledge. However, our 
findings are those of real life practise and would be supported by other groups who have shown that 
inadequate evaluation of IgA deficiency occurs frequently when testing for CD.57 Nevertheless, had 
we excluded such patients from our analysis then the prevalence of SNCD would have been 27.7% 
(n=53/191) instead of the 31% (n=62/200) stated. Thirdly, we have unanswered questions in those in 
whom no cause was found (so called idiopathic/unclassified sprue) but spontaneously normalised 
duodenal biopsies whilst consuming high-dose gluten. A recent case series has highlighted that self-
limiting enteropathies can occur in the context of gastrointestinal infections,23 which raises the 
possibility that our patients may have experienced a similar insult although this was not recalled 
from their clinical history nor isolated from stool cultures. Furthermore, these individuals had their 
repeat biopsy performed on average nine months after the index case which had shown villous 
atrophy. We do not know when their histology started improving and at what exact time-point it had 
normalised. Had the biopsies been performed earlier then these patients may still have had 
persisting villous atrophy and, in those with the correct HLA-DQ genotype, subsequently categorised 
as having CD. However, our study was performed pragmatically and is a reflection of routine out-
patient clinical practise. Nevertheless, future research studies should aim to perform biopsies at 
sequential time-points. Finally, of those carrying the HLA-DQ genotype it could be hypothesised that 
these individuals may still belong to the spectrum of CD and have simply experienced an 
unexplained gastrointestinal insult transiently manifesting as SNVA but having not yet reached the 
cumulative threshold required for CD to become apparent.58 Hence, longitudinal follow-up data is 
now required in this particular group. 
Other studies 
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To our knowledge only one other study has evaluated diagnostic outcomes in SNVA.16 This was 
performed by the New York group who evaluated 72 complex case referrals of SNVA over a 10-year 
period. The investigators found that 22% (n=16/72) of their SNVA cases were due to olmesartan-
related enteropathy.16 This novel association has generated substantial interest and is of importance 
given its presentation may be that of a severe form of enteropathy necessitating hospitalization for 
the management of intractable diarrhoea, weight loss, dehydration, hypotension, acute renal failure 
and metabolic acidosis.16,42-45 Yet, these findings are in contrast to ours where the use of A2RB was 
seen in 8 of 200 SNVA cases, with A2RB a responsible cause for enteropathy in 2 patients; overall 
prevalence of A2RB-enteropathy being 1% (n=2/200). In the other 6 patients we found an alternate 
aetiology for SNVA with patients well maintained on their A2RB; these include CD (n=2), giardiasis 
(n=1), eosinophillic enteritis (n=1), small bowel bacterial overgrowth (n=1), and one lost to follow-
up. Given that A2RB including olmesartan are dispensed in the UK then the discrepancy in results 
raises two main points. Firstly, the high prevalence of olmesartan-related enteropathy reported 
elsewhere may not be reflecting SNVA in general but rather groups overseeing and presenting the 
outcomes of cases referred from wide-catchment areas with presumed “poorly 
responsive/refractory CD”.16 In fact, the initial case series highlighting this association came from the 
Mayo clinic where 22 patients with olmesartan-related enteropathy were reported following 
referrals from 16 US states over a 3-year period.42 Following on, a nationwide multicentre French 
survey identified 36 patients with olmesartan-related enteropathy.44 Most recently, the crude 
incidence rates of olmesartan and other A2RB-enteropathy in France has been calculated at 5.6 and 
1.8 per 100 000 patient years, respectively.45 These findings suggest that olmesartan- and in 
particular other A2RB-related enteropathies are rare adverse events. Secondly, despite the growing 
awareness of A2RB-related enteropathy clinicians must still remain vigilant that on occasions A2RB 
will merely be innocent bystanders and an alternate aetiology for SNVA will be found. 
Conclusion 
This large UK centre study provides a prospective, systematic, and clinically pragmatic evaluation of 
SNVA. We have shown that most patients with SNVA do not have CD or angiotensin-2-receptor-
blocker enteropathy. Further, a subgroup in whom no cause is found will show spontaneous 
histological resolution whilst still consuming gluten and this phenomenon requires further 
evaluation. The presence of non-white ethnicity was found to be a factor predicting a non-coeliac 
cause, in particular infective aetiology.  
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Table 1: Studies where coeliac serology have shown low sensitivities in villous atrophy 
Coeliac serology as defined by endomysial and/or tissue transglutaminase antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
First author Year Country No of villous 
atrophy cases 
Positive coeliac 
serology, n (%)  
Negative coeliac 
serology, n (%) 
Rostami8 1999 Netherlands 69 42 (61%) 27 (39%) 
Dickey9 2000 Northern Ireland 89 69 (78%) 20 (22%) 
Dahele10 2001 Scotland 53 42 (79%) 11 (21%) 
Dahele11 2001 Scotland 114 92 (81%) - 99 (87%) 15 (11%)-22(19%) 
 
Clemente12 2002 Italy 111 95 (86%) 16 (14%) 
Abrams13 2004 United States 115 74 (64%) 41 (36%) 
Collin14 2005 European 
Multicentre 
126 112 (89%) - 118 (94%) 8 (6%)-14 (11%) 
Salmi15 2006 Finland 177 151 (85%) 26 (15%) 
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Figure 1: Step-wise proposed algorithm used to investigate and diagnose causes of SNVA 
Step-wise algorithm to investigate seronegative villous atrophy (SNVA) 
 
1. Exclude immunoglobulin/selective IgA deficiency. Check for raised IgG coeliac serology if needed. 
 
2. Review clinical history and medication. 
 
3. Seek opinion from expert GI histopathologist i.e. neutrophils, granulomas, crypt abscesses, duodenitis  
 
4. a) Check HLA-DQ2 and DQ8 status.  
 
b) Check HIV status, Tuberculosis quantiferon, anti-enterocyte and anti-goblet cell antibodies. 
 
c) Check stool for giardia antigen, bacterial and viral enteritis. 
 
d) Repeat upper GI endoscopy following a gluten-challenge of 10g/day for six weeks. Obtain further 
duodenal biopsies, H.pylori rapid urease test, small bowel aspirate, and Whipples PCR. 
 
e) Consider ileo-colonoscopy with biopsies if lower gastro-intestinal symptoms.  
 
5. Further investigations i.e. small bowel video capsule endoscopy at the discretion of clinician and 
depending on local availability. 
 
 
 
Diagnosis of SNCD  
(any of the following criteria) 
 
1. IgA deficiency with raised IgG coeliac 
serology 
 
2. Co-existing dermatitis herpetiformis 
 
3. First degree family history of coeliac disease 
with subsequent response to a GFD. 
 
4. HLA DQ2 and/or DQ8 positive, no alternate 
cause found, persisting villous atrophy on 
gluten-challenge. Subsequent clinical +/- 
histological response to a GFD. 
Diagnosis of SN-non-CD  
(any of the following criteria) 
 
1. HLA DQ2 and DQ8 negative. 
 
2. HLA DQ2 and/or DQ8 positive with confident 
alternate cause identified. Subsequent 
treatment leads to clinical + histological 
improvement. 
 
3. HLA DQ2 and/or DQ8 positive with no 
alternate cause identified. Spontaneous 
histological resolution whilst still on a gluten-
containing diet. 
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Table 2: Baseline characteristics of SNVA subjects and SPCD controls 
 Total SNVA        
(n=200) 
SN-non-CD     
(n=138; 69%) 
SNCD               
(n=62; 31%) 
P-value  
(between SNCD 
and SN-non-CD) 
SPCD controls 
(n=343) 
P-value      
(SPCD controls vs. 
SN-non-CD) 
P-value      
(SPCD controls vs. 
SNCD) 
Demographics 
Mean-age ± SD 51.2 ± 17.6 51.4 ± 17.3 50.9 ± 18.2 0.89 43.5 ± 17.3 <0.001 0.002 
Female, n 127 (63.5%) 84 (60.9%) 43 (69.4%) 0.25 242 (70.6%) 0.04 0.85 
White ethnicity, n 165 (82.5%) 105 (76.1%)            60 (96.8%)           <0.001 307 (89.5%) <0.001 0.1 
Sheffield city resident, n 166 (83%) 116 (84%) 50 (80.6%) 0.55 343 (100%) <0.001 <0.001 
Clinical symptoms 
Diarrhoea, n 120 (60%) 84 (61%) 36 (58.1%) 0.71 153 (44.6%) 0.001 0.05 
Weight Loss, n 71 (35.5%) 52 (37.7%) 19 (30.6%) 0.34 40 (11.7%) <0.001 <0.001 
Abdominal pain, n 98 (49%) 69 (50%) 29 (46.8%) 0.67 121 (35.3%) 0.003 0.08 
Bloating, n 62 (31%) 43 (31.2%) 19 (30.6%) 0.94 102 (29.7%) 0.76 0.89 
Dyspepsia, n 28 (14%) 24 (17.4%) 4 (6.5%) 0.04 19 (5.5%) <0.001 0.79 
Reflux, n 32 (16%) 24 (17.4%) 8 (12.9%) 0.42 27 (7.9%) 0.002 0.19 
Nausea, n 39 (19.5%) 27 (19.6%) 12 (19.4%) 0.97 22 (6.4%) <0.001 0.001 
Constipation, n 32 (16%) 24 (17.4%) 8 (12.9%) 0.42 52 (15.2%) 0.54 0.65 
Fatigue, n 32 (16%) 19 (13.8%) 13 (21%) 0.2 91 (26.5%) 0.003 0.36 
Past medical history 
Autoimmunity, n 37 (18.5%) 18 (13%) 19 (30.6%) 0.003 72 (21%) 0.04 0.09 
Family history of CD, n 7 (3.5%) 0 (0%) 7 (11.2%) <0.001 55 (16%) <0.001 0.34 
Recent gastroenteritis-type history, n 23 (11.5%) 18 (13%) 5 (8.1%) 0.31 8 (2.3%) <0.001 0.03 
Crohn’s disease, n 1 (0.5%) 1 (0.7%) 0 (0%) 0.5 1 (0.3%) 0.49 1.0 
Lymphoproliferative disorders, n 4 (2%) 3 (2.2%) 1 (1.6%) 1.0 2 (0.6%) 0.15 0.39 
HIV, n 2 (1%) 2 (1.4%) 0 (0%) 1.0 1 (0.3%) 0.2 1.0 
Tuberculosis, n 2 (1%) 2 (1.4%) 0 (0%) 1.0 1 (0.3%) 0.2 1.0 
Medication 
A2RB, n 8 (4%) 6 (4.3%) 2 (3.2%) 1.0 8 (2.3%) 0.23 0.66 
Aspirin, n 29 (14.5%) 21 (15.2%) 8 (12.9%) 0.67 29 (8.5%) 0.03 0.26 
NSAIDs, n 19 (9.5%) 16 (11.6%) 3 (4.8%) 0.13 11 (3.2%) <0.001 0.46 
Methotrexate, n 2 (1%) 1 (0.7%) 1 (1.6%) 0.5 2 (0.6%) 1.0 0.39 
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Mycophenolate, n 1 (0.5%) 1 (0.7%) 0 (0%) 1.0 1 (0.3%) 0.49 1.0 
Azathioprine, n 0 (0%) 0 (0%) 0 (0%) - 3 (0.9%) 0.56 1.0 
Bloods 
Anaemia, n 61/198(30.8%) 43/137 (31.4%) 18/61 (29.5%) 0.79 154/343 (44.9%) 0.007 0.03 
Low ferritin, n 75/190 (39.5%) 51/130 (39.2%) 24/60 (40%) 0.92 207/333 (62.2%) <0.001 0.001 
Low folate, n 35/192 (18.3%) 28/131 (21.4%) 7/61 (11.5%) 0.1 100/333 (30%) 0.06 0.003 
Low vitamin B12, n 31/193 (16.1%) 21/131 (16%) 10/62 (16.1%) 0.99 61/331 (18.4%) 0.54 0.67 
Low calcium, n 22/186 (11.8%) 17/126 (13.5%) 5/60 (8.3%) 0.31 28/332 (8.4%) 0.1 0.98 
Low albumin, n 21/198 (10.6%) 19/137 (13.9%) 2/61 (3.3%) 0.03 16/336 (4.8) 0.001 1.0 
Raised ESR and/or CRP, n 51/192 (26.6%)  40/132 (30.3%) 11/60 (18.3%) 0.08 82/324 (25.3%) 0.28 0.25 
HLA-DQ2 and/or DQ8 positive, n 118/193 (61%) 58/133(43.6%) 60/60(100%) <0.001 112/112 (100%) <0.001 1.0 
Duodenal histology 
Intraepithelial lymphocytosis, n 177 (88.5%) 116 (84%) 61 (98.4%) 0.003 343 (100%) <0.001 0.15 
Crypt hyperplasia, n 177 (89%) 117 (84.8%) 61 (98.4%) 0.003 343 (100%) <0.001 0.15 
Partial villous atrophy , n 
Subtotal villous atrophy, n 
Total villous atrophy, n 
159 (79.5%) 
25 (12.5%) 
16 (8%) 
120 (87%) 
10 (7.2%)
   
         
8 (5.8%) 
39(62.9%) 
15 (24.2%) 
 8 (12.9%) 
 
<0.001 
82 (23.9%) 
144 (42%) 
117 (34.1%) 
 
<0.001 
 
<0.001 
 
A2RB, Angiotensin-2-receptor-blockers; CD, Coeliac disease; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; HIV, Human immunodeficiency virus; HLA, Human Leukocyte 
antigen; NSAIDS, Non-steroidal anti-inflammatory drugs; SNVA, Seronegative villous atrophy; SNCD, Seronegative coeliac disease; SN-non-CD, Seronegative non-coeliac disease; SPCD: 
Seropositive coeliac disease 
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Figure 2: Causes of SNVA at a UK centre (n=200) 
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Table 3: Characteristics and diagnostic outcomes in non-whites with SNVA seen at a UK centre 
 
Case Age/Sex Ethnicity Symptoms Marsh 
Grading 
HLA-DQ2/8 
status 
Aetiology of SNVA 
1 28/female Pakistan Abdominal pain, reflux, weight 
loss 
PVA + Helicobacter pylori induced duodenitis 
2 29/male Oman Diarrhoea, nausea, bloating, 
dyspepsia 
PVA + No cause found – SNVA resolved 
3 30/female Tunisia Diarrhoea, anaemia, bloating PVA + Giardiasis 
4 33/male Ghana Diarrhoea, weight loss, abdominal 
pain, cough 
PVA + Sarcoidosis 
5 39/male Somalia Diarrhoea, bloating, abdominal 
pain 
PVA + Small intestinal bacterial overgrowth 
6 43/male Iran Nausea, dyspepsia, cough, weight 
loss 
PVA + Tuberculosis 
7 49/female Pakistan Anaemia, abdominal pain, 
bloating, reflux, fatigue, 
constipation 
PVA + Small intestinal bacterial overgrowth 
8 49/female India Anaemia PVA + Helicobacter pylori induced duodenitis 
9 49/female Somalia Diarrhoea, bloating, abdominal 
pain, anaemia 
PVA + No cause found – SNVA resolved 
10 58/female India Abdominal pain, dyspepsia, 
bloating 
PVA + No cause found – SNVA resolved 
11 65/female Iraq Abdominal pain, bloating, 
dyspepsia, anaemia 
PVA + Whipple’s disease 
12 82/female Yemen Abdominal pain, bloating, reflux PVA + Peptic duodenitis 
13 18/male Pakistan Anaemia SVA + Coeliac disease.  
Associated Sjogren’s and IgA deficiency 
14 31/female Pakistan Diarrhoea, anaemia, nausea, 
bloating 
SVA + Mycobacterium avium,  
Helicobacter pylori induced duodenitis 
15 53/female India Anaemia SVA + NSAIDs 
16 71/male Bangladesh Anaemia, dyspepsia, bloating SVA + Helicobacter pylori induced duodenitis 
17 30/male Iran Dyspepsia, reflux, weight loss SVA + Coeliac disease 
18 22/female Pakistan Abdominal pain, nausea, fatigue PVA - Helicobacter pylori induced duodenitis 
19 26/female Yemen Anaemia, weight loss, abdominal 
pain. nausea, bloating, fatigue 
PVA - Helicobacter pylori induced duodenitis 
20 35/female Caribbean Diarrhoea, bloating, abdominal 
pain 
PVA - Helicobacter pylori induced duodenitis 
21 36/male Iraq Diarrhoea, abdominal pain, 
bloating 
PVA - NSAIDs 
22 38/male Zambia Anaemia, abdominal pain PVA - Tuberculosis,  
Helicobacter pylori induced duodenitis 
23 38/female Bangladesh Diarrhoea, anaemia, abdominal 
pain, fatigue 
PVA - Helicobacter pylori induced duodenitis 
24 45/female Pakistan Anaemia PVA - Helicobacter pylori induced duodenitis 
25 47/female Vietnam Dyspepsia PVA - No cause found – lost to follow-up 
26 47/male Pakistan Abdominal pain, weight loss, 
bloating, reflux 
PVA - Peptic duodenitis 
27 47/female Pakistan Diarrhoea, bloating PVA - Ascariasis 
28 49/female Bangladesh Diarrhoea, anaemia, fatigue, 
fevers, night sweats 
PVA - Tuberculosis 
29 50/male Caribbean Diarrhoea, abdominal pain, reflux PVA - Helicobacter pylori induced duodenitis 
30 51/female Yemen Abdominal pain, weight loss PVA - Helicobacter pylori induced duodenitis 
31 54/female Bangladesh Diarrhoea, weight loss, abdominal 
pain, dyspepsia, fatigue, 
constipation 
PVA - No cause found – SNVA resolved 
32 75/female Hong Kong Diarrhoea, weight loss, anaemia PVA - Small intestinal bacterial overgrowth 
33 35/male Bangladesh Reflux, dyspepsia, weight loss SVA - Helicobacter pylori induced duodenitis 
34 57/male Yemen Diarrhoea, weight loss PVA not stated Helicobacter pylori induced duodenitis 
35 25/male Caribbean Diarrhoea SVA not stated HIV enteropathy,  
Helicobacter pylori induced duodenitis 
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Figure 3: Duodenal histology of SNVA and SPCD control  
 
Plates A to D: SPCD control. A white woman presenting with anaemia and positive serum IgA endomysial antibody. 
Duodenal biopsy demonstrated subtotal villous atrophy when stained with haemotoxylin and eosin (H&E). It can also be 
seen that there is an increased number of intra-epithelial lymphocytes stained by the pan-lymphocyte marker CD3. 
Furthermore, staining of antibodies against different intraepithelial lymphocyte phenotype revealed that they are all of the 
CD8-T-cytotoxic stain and not CD4-T-helper cells. This is the classical pattern of coeliac disease. 
Plates E to H: SNCD patient. A white woman presenting with diarrhoea. Serum IgA endomysial antibodies were negative 
but duodenal biopsy showed subtotal villous atrophy. There were increased intraepithelial lymphocytes noted following 
CD3 pan-lymphocyte stain, which on immunophenotypic differentiation revealed CD8-T-cytotoxic cells but not CD4-T-
helper cells. Her HLA-DQ2 was positive, no alternate cause was found, and she responded to a gluten-free diet. 
Plates I to L: SN-non-CD patient. Bengali woman presenting with diarrhoea, anaemia, night sweats and fevers. Her serum 
IgA endomysial antibody was negative but duodenal biopsy showed partial villous atrophy with raised intraepithelial 
lymphocytes. She stained positive for CD8-T-cytotoxic cells but also for CD4-T-helper cells. This could have been mistaken 
for refractory coeliac disease. However, her HLA-DQ2/8 genotype was negative and on microbiology assessment her 
duodenal sample revealed mycobacteria (supplementary picture). She was commenced on anti-tuberculosis therapy. 
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Figure 4: Kaplan-Meier estimated survival curves for SNVA and SPCD controls 
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Supplementary picture 
A       B 
 
Mycobacterium demonstrating acid-alcohol fast staining using Ziehl-Neelsen’s method following 
culture in liquid medium (A) and on direct staining of tissue sample (B). The lipid rich mycolic acids in 
the organism’s cell wall prevent decolorisation with acid-alcohol after initial staining with carbol 
fuchsin (red) 
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